Towards new imaging markers for in vivo detection of pathologies such as Alzheimer’s or diabetes

06 January 2021 par Isabelle Frapart
Researchers from CBM and LCC (Toulouse) have designed a new probe to detect amyloid deposits biomarkers of these diseases

The accumulation of aggregates of certain non-soluble peptides in tissues is characteristic of several pathologies, such as Alzheimer's and Parkinson's diseases, or diabetes. The detection of these amyloid deposits by in vivo imaging would be very useful for an early diagnostic and a better understanding of the molecular mechanisms of these diseases. Researchers from the Molecular Biophysics Center (CBM) and the Toulouse Coordination Chemistry Laboratory (LCC), in collaboration with Portuguese and Hungarian scientists, have taken an important step forward in the design of imaging agents that specifically recognize these amyloid deposits. This work is on the cover of Chemistry A European Journal.

Read more on the website of CNRS Chemistry Institute (INC)